5'-cyclopropylcarbamoyl-2'-methyl-biphenyl-4-carboxylic acid | 515131-53-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5'-cyclopropylcarbamoyl-2'-methyl-biphenyl-4-carboxylic acid
• 英文别名: 3'-([(cyclopropylamino)carbonyl]-6'-methyl-1,1'-biphenyl-4-yl)carboxylic acid；{3'-[(Cyclopropylamino)carbonyl]-6'-methyl-biphen-4-yl} carboxylic acid；4-[5-(cyclopropylcarbamoyl)-2-methylphenyl]benzoic acid
• CAS: 515131-53-0
• 化学式: C₁₈H₁₇NO₃
• 分子量: 295.338
• InChiKey: SMZGRHROQWRXEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5'-cyclopropylcarbamoyl-2'-methyl-biphenyl-4-carboxylic acid 在 氨 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 4.0h， 以91%的产率得到6-methyl-biphenyl-3,4'-dicarboxylic acid 4'-amide-3-cyclopropylamide
  参考文献：
  名称：

  P-38 kinase inhibitors

  摘要：

  提供了用于调节p38激酶活性的化合物和组合物，包括p38α和p38β激酶。还提供了用于治疗、预防或缓解p38激酶介导的疾病或紊乱的一种或多种症状的方法。

  公开号：

  US20050020590A1
• 作为产物：
  描述：

  5'-Cyclopropylcarbamoyl-2'-methyl-biphenyl-4-carboxylic acid methyl ester 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 以86%的产率得到5'-cyclopropylcarbamoyl-2'-methyl-biphenyl-4-carboxylic acid
  参考文献：
  名称：

  P-38 kinase inhibitors

  摘要：

  提供了用于调节p38激酶活性的化合物和组合物，包括p38α和p38β激酶。还提供了用于治疗、预防或缓解p38激酶介导的疾病或紊乱的一种或多种症状的方法。

  公开号：

  US20050020590A1

文献信息

• [EN] HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS<br/>[FR] DERIVES DE BIPHENYL SUBSTITUES EN HETEROARYLE SOUS FORME D'INHIBITEURS DE P38 KINASE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003093248A1

  公开（公告）日：2003-11-13

  Compounds of formula (I) are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.

  式（I）的化合物是p38激酶的抑制剂，可用于治疗由p38激酶活性介导或由p38活性产生的细胞因子介导的疾病状态或疾病。
• 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
  申请人：——

  公开号：US20040267012A1

  公开（公告）日：2004-12-30

  Compounds of formula (I): wherein when m is 0 to 4 R1 is selected from C1-6alkyl, C3-7cycloalkyl, C2-6alkenyl, —SO2NR4R5, —CONR4R5 and —COOR4; and when m is 2 to 4 R1 is additionally selected from C1-6alkoxy, hydroxy, NR4R5, —NR4SO2R5, —NR4SOR5, —NR4COR5, and —NR4CONR4R5; R2 is selected from hydrogen, C1-6alkyl and —(CH2)n-C3-7cycloalkyl; R3 is the group —CO—NH—(CH2)p-R6; U is selected from methyl and halogen; W is selected from methyl and chlorine; V and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4 wherein each carbon atom of the resulting carbon chain may be optionally substituted with one or two groups selected independently from C1-6alkyl; n is selected from 0, 1, 2 and 3; p and r are independently selected from 0, 1 and 2; s is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors. 1

  化学式为(I)的化合物：其中当m为0至4时，R1从C1-6烷基，C3-7环烷基，C2-6烯基，—SO2NR4R5，—CONR4R5和—COOR4中选择；当m为2至4时，R1还可从C1-6烷氧基，羟基，NR4R5，—NR4SO2R5，—NR4SOR5，—NR4COR5和—NR4CONR4R5中选择；R2从氢，C1-6烷基和—（CH2）n-C3-7环烷基中选择；R3为—CO—NH—（ ）p-R6基团；U从甲基和卤素中选择；W从甲基和氯中选择；V和Y各自独立地从氢，甲基和卤素中选择；m从0、1、2、3和4中选择，其中所得碳链的每个碳原子可以选择性地被一个或两个从C1-6烷基中独立选择的基团取代；n从0、1、2和3中选择；p和r独立地从0、1和2中选择；s从0、1和2中选择；或其药学上可接受的盐或溶剂，以及它们作为药物的用途，特别是作为p38激酶抑制剂。
• 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
  申请人：Glaxo Group Limited

  公开号：US07208629B2

  公开（公告）日：2007-04-24

  Compounds of formula (I): wherein when m is 0 to 4 R1 is selected from C1–6alkyl, C3–7cycloalkyl, C2–6alkenyl, —SO2NR4R5, —CONR4R5 and —COOR4; and when m is 2 to 4 R1 is additionally selected from C1–6alkoxy, hydroxy, NR4R5, —NR4SO2R5, —NR4SOR5, —NR4COR5, and —NR4CONR4R5; R2 is selected from hydrogen, C1–6alkyl and —(CH2)n-C3–7cycloalkyl; R3 is the group —CO—NH—(CH2)p-R6; U is selected from methyl and halogen; W is selected from methyl and chlorine; V and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4 wherein each carbon atom of the resulting carbon chain may be optionally substituted with one or two groups selected independently from C1–6alkyl; n is selected from 0, 1, 2 and 3; p and r are independently selected from 0, 1 and 2; s is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors

  式（I）的化合物：其中当m为0至4时，R1从C1-6烷基，C3-7环烷基，C2-6烯基，—SO2NR4R5，—CONR4R5和—COOR4中选择；当m为2至4时，R1还从C1-6烷氧基，羟基，NR4R5，—NR4SO2R5，—NR4SOR5，—NR4COR5和—NR4CONR4R5中选择；R2从氢，C1-6烷基和—（CH2）n-C3-7环烷基中选择；R3为—CO—NH—（ ）p-R6基团；U从甲基和卤素中选择；W从甲基和氯中选择；V和Y各自独立地从氢，甲基和卤素中选择；m从0、1、2、3和4中选择，其中所得碳链的每个碳原子可以选择性地用一个或两个从C1-6烷基中独立选择的基团替换；n从0、1、2和3中选择；p和r各自独立地从0、1和2中选择；s从0、1和2中选择；或其药学上可接受的盐或溶剂，以及它们作为药物的用途，特别是作为p38激酶抑制剂。
• P-38 Kinase Inhibitors
  申请人：Lang Hengyuan

  公开号：US20100234404A1

  公开（公告）日：2010-09-16

  Compounds and compositions for modulating the activity of p38 kinases are provided, including p38α, and p38β kinase. Methods for treating, preventing or ameliorating one or more symptoms of a p38 kinase mediated disease or disorder are also provided.

  本文提供了调节p38激酶活性的化合物和组合物，包括p38α和p38β激酶。还提供了治疗、预防或改善p38激酶介导的疾病或疾病症状的方法。
• Biphenylcyclopropylamides as p-38 Kinase inhibitors
  申请人：NOVARTIS AG

  公开号：EP1990338A2

  公开（公告）日：2008-11-12

  Compounds and compositions for modulating the activity of p38 kinases are provided, including p38α and p38β kinase. Methods for treating, preventing or ameliorating one or more symptoms of a p38 kinase mediated disease or disorder are also provided.

  提供了调节 p38 激酶活性的化合物和组合物，包括 p38α 和 p38β 激酶。还提供了治疗、预防或改善 p38 激酶介导的疾病或紊乱的一种或多种症状的方法。